Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Choose the Best Web based Advertising Degree Program for Your Objectives - 220-year-old who threatened German train attack remanded in custody
- 3Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
- 4The most effective method to Recuperate After a Dental Embed Strategy: A Far reaching Guide
- 5China's Normal Ponders: A Visual Excursion
- Etymological Experiences on the Wireless transmissions: A Survey of \Learning in a hurry\ Language Web recording
- Transcript: Scott Gottlieb on "Face the Nation with Margaret Brennan," Dec. 7, 2025
- Step by step instructions to Contrast Lab Jewels and Regular Ones
- Spain’s Picos de Europa: What to see and do in ‘the world’s most beautiful place’
- Big Bear glows with big stars | Space photo of the day for Dec. 31, 2025
- 25 Most Beautiful Villages in France You Can Actually Visit
- Merz postpones Norway trip for Belgium talks on frozen Russian assets
- Quantum Computing’s Next Major Breakthroughs Could Come From Australia
- Why home maintenance deserves a spot in the annual health and budget plans
